Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 19/20 | 0.75 |
| ▸ | STAT6 | P42226 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15623875 | 1.00 | SLC29A1 (0.75) | SLC29A1STAT6 | |
| SCHEMBL21192198 | 1.00 | SLC29A1 (0.75) | SLC29A1STAT6 | |
| SCHEMBL6470156 | 1.00 | SLC29A1 (0.75) | SLC29A1STAT6 | |
| SCHEMBL3675456 | 1.00 | SLC29A1 (0.75) | SLC29A1STAT6 | |
| SCHEMBL7134319 | 0.88 | SMN1; SMN2 (0.77) | SLC29A1STAT6 | |
| SCHEMBL30089484 | 0.88 | SMN1; SMN2 (0.77) | SLC29A1STAT6 | |
| SCHEMBL672036 | 0.88 | SMN1; SMN2 (0.77) | SLC29A1STAT6 | |
| SCHEMBL672035 | 0.88 | SMN1; SMN2 (0.77) | SLC29A1STAT6 | |
| SCHEMBL240981 | 0.88 | SMN1; SMN2 (0.77) | SLC29A1STAT6 | |
| SCHEMBL19488384 | 0.88 | SMN1; SMN2 (0.77) | SLC29A1STAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109933-A1 | NOVEL NUCLEOSIDE ANALOGS AND USE THEREOF IN THERAPEUTIC TREATMENT | CORNELL UNIVERSITY (US) | 2024-04-04 | — | — | US | disclosed |
| US-20190225643-A1 | NOVEL NUCLEOSIDE ANALOGS AND USE THEREOF IN THERAPEUTIC TREATMENT | CORNELL UNIVERSITY (US) | 2019-07-25 | — | — | US | disclosed |
| WO-2017180981-A1 | NOVEL NUCLEOSIDE ANALOGS AND USE THEREOF IN THERAPEUTIC TREATMENT | CORNELL UNIVERSITY (US) | 2017-10-19 | — | — | WO | disclosed |
| EP-2711009-A1 | Compounds for use in treating or preventing primary and metastatic breast and prostate cancer | Institut Univ. de Ciència i Tecnologia, S.A. (ES) | 2014-03-26 | — | — | EP | disclosed |
| WO-2005078125-A2 | ITPASE GENE POLYMORPHISMS ASSOCIATED WITH ADVERSE DRUG REACTIONS TO AZATHIOPRINE THERAPY | GUY'S AND ST. THOMAS' NHS FOUNDATION TRUST (GB) | 2005-08-25 | — | — | WO | disclosed |
| EP-0755255-A4 | TREATMENT OF TOXOPLASMOSIS | RES CORP TECHNOLOGIES INC (US) | 2002-07-24 | — | — | EP | disclosed |
| US-5773424-A | PARASITICIDE | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-06-30 | — | — | US | disclosed |
| EP-0755255-A1 | TREATMENT OF TOXOPLASMOSIS | UNIVERSITY OF ALABAMA, BIRMINGHAM RESEARCH FOUNDATION (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1996018398-A1 | TREATMENT OF TOXOPLASMOSIS | THE UNIVERSITY OF ALABAMA AT BIRMINGHAM RESEARCH FOUNDATION (US) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225643-A1 | NOVEL NUCLEOSIDE ANALOGS AND USE THEREOF IN THERAPEUTIC TREATMENT | DCK, NME4, ENTPD5 | SLC29A1 80/4885STAT6 915/4885 |
| US-20240109933-A1 | NOVEL NUCLEOSIDE ANALOGS AND USE THEREOF IN THERAPEUTIC TREATMENT | DCK, NME4, ENTPD5 | SLC29A1 80/4885STAT6 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.